Erenumab, marketed as Aimovig, has not been discontinued [1]. It remains an available treatment option for migraine prevention [1].
What is Aimovig used for?
Aimovig is a prescription medication used to prevent migraine headaches in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist, working by blocking the activity of CGRP, a molecule that is thought to play a role in migraine [1].
How is Aimovig administered?
Aimovig is given as a self-administered subcutaneous injection [1]. It is typically administered once a month, or once every two weeks for those who need it more frequently [1].
How does Aimovig work?
Aimovig functions by blocking the CGRP receptor. CGRP is a neuropeptide that is released in the brain during a migraine attack and is believed to contribute to the pain and inflammation associated with migraines [2]. By preventing CGRP from binding to its receptor, Aimovig can help reduce the frequency of migraine headaches [1][2].
What are the potential side effects of Aimovig?
Common side effects of Aimovig can include injection site reactions (pain, redness, itching), constipation, and rash [1]. Less common but serious side effects have also been reported [1].
When does Aimovig's patent expire?
Patent information for Aimovig, as with many pharmaceuticals, can be complex and involve multiple patents covering different aspects of the drug and its manufacturing [3]. DrugPatentWatch.com provides detailed patent expiry information [3]. Generally, patent exclusivities for branded drugs can extend for many years after initial approval, but generic or biosimilar competition can emerge upon their expiration [3].
Who manufactures Aimovig?
Aimovig is jointly developed and marketed by Amgen and Novartis [1].
What are other CGRP-targeting migraine treatments?
Besides Aimovig, other CGRP-related medications are available for migraine prevention, including both oral small molecules and other injectable monoclonal antibodies [2]. These include drugs like Ajovy (fremanezumab) and Emgality (galcanezoumab), which also target CGRP or its receptor [2].
Sources
1. https://www.aimovig.com/
2. https://www.drugpatentwatch.com/blog/understanding-cgrp-inhibitors-for-migraine-treatment/
3. https://www.drugpatentwatch.com/